Table 1 Small molecule antibacterial drugs and β-lactamase inhibitor (BLI) combinations launched from January 2013 to December 2022
From: Antibiotics in the clinical pipeline as of December 2022
Year approved | Drug namea,b | Class | Country of first approval | Therapeutic indication(s) | Lead source |
|---|---|---|---|---|---|
Small molecule drugs | |||||
2014 | delamanid | nitroimidazole | Europe | TB | S |
2014 | dalbavancin | glycopeptide | USA | G+ve SSSI | NP |
2014 | oritavancin | glycopeptide | USA | G+ve SSSI | NP |
2014 | tedizolid phosphate (prodrug) | oxazolidinone | USA | G+ve cSSSI | S |
2014 | nemonoxacin | quinolone | Taiwan | G+ve /G-ve cSSSI | S |
2014 | morinidazolec | nitroimidazole | China | G+ve/G-ve gynecological and suppurative appendicitis | S |
2014 | finafloxacind | fluoroquinolone | USA | acute otitis externa | S |
2015 | zabofloxacin | fluoroquinolone | South Korea | G+ve/G-ve CABP | S |
2017 | delafloxacin | fluoroquinolone | USA | G+ve/G-ve ABSSSI and CABP | S |
2018 | plazomicin | aminoglycoside | USA | G-ve UTI | NP |
2018 | eravacycline | tetracycline | Europe | G+ve/G-ve IAI | NP |
2018 | omadacycline | tetracycline | USA | G+ve/G-ve CABP and ABSSSI | NP |
2018 | sarecyclined | tetracycline | USA | G+ve acne | NP |
2019 | pretomanid | nitroimidazole | USA | TB | S |
2019 | lefamulin | pleuromutilin | USA | G+ve/G-ve CABP | NP |
2019 | lascufloxacin | fluoroquinolone | Japan | G+ve/G-ve CABP and sinusitis | S |
2019 | cefiderocol | cephalosporin siderophore | USA | G-ve cUTI and bacterial infections | NP |
2020 | levonadifloxacin (1); alalevonadifloxacin (2) (prodrug) | fluoroquinolone | India | G+ve/G-ve ABSSSI | S |
2021 | contezolid (4) | oxazolidinone | China | G+ve cSSSI | S |
BL/BLI combination drugs | |||||
2014 | Zerbaxa: ceftolozane + tazobactame | BL + BLI | USA | G-ve cUTI, cIAI and HAP/VAP | NP + NP |
2015 | Avycaz: avibactam (80)b + ceftazidimee | DBO BLI + BL | USA | G-ve cUTI, cIAI and HAP/VAP | S + NP |
2017 | Vabomere/Vaborem: vaborbactamb + meropeneme (66) | boronate BLI + BL | USA | G-ve cUTI, cIAI and HAP/VAP | S + NP |
2019 | Recarbrio: relebactam + imipenem (77)e + cilastatin (78)e | DBO BLI + BL+ renal dehydropeptidase inhibitor | USA | G-ve cUTI, cIAI and HAP/VAP | S + NP + S |
